Detection of lymphomatous bone marrow involvement with magnetic resonance imaging [see comments]

Autor: HM Shulman, AF Shields, B A Porter, BR Hoane

Publikováno v: Blood. 78:728-738

We reviewed magnetic resonance (MR) staging examinations of 98 patients with malignant lymphoma who failed other therapy and were under evaluation for bone marrow transplantation. MR scan results were compared with blind posterior iliac crest aspirat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ca87485885ed483ed2e632753ea85ea
https://doi.org/10.1182/blood.v78.3.728.728

Gastrointestinal radiographic features of human graft-vs.-host disease

Autor: ED Thomas, RR Greening, George B. McDonald, GE Sale, JD Fisk, HM Shulman

Publikováno v: American Journal of Roentgenology. 136:329-336

Following allogeneic bone marrow transplantation, graft-versus-host disease (GVHD) develops when the foreign donor lymphoid graft mounts an immunologic reaction against the skin, liver, and gastrointestinal tract of the host. The GVHD syndrome is cha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29a0f4368b23d2c92525e1091d51faa9
https://doi.org/10.2214/ajr.136.2.329

Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression

Autor: KM Sullivan, HM Shulman, R Storb, PL Weiden, RP Witherspoon, GB McDonald, MM Schubert, K Atkinson, ED Thomas

Publikováno v: Blood. 57(2)

Fifty-two of 175 (30%) survivors of allogeneic marrow transplantation developed chronic graft-versus-hose diseases (GVHD). Five with limited chronic GVHD had an indolent clinical course with involvement of only the skin and liver. Forty-seven with ex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b70cddc90232f7466655426f9c2d3130
https://pubmed.ncbi.nlm.nih.gov/7004534

Hepatic veno-occlusive disease following sirolimus-based immune suppression.

Autor: Khimani F; BMTCI H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA. Farhad.Khimani@moffitt.org., McDonald GB; GI/Hepatology, Fred Hutchinson Cancer Research Center, Seattle, USA., Shulman HM; Pathology, University of Washington, Seattle, USA., Betts B; BMTCI H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA., Locke F; BMTCI H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA., Fernandez H; Moffitt Malignant Hematology and Cellular Therapy, Memorial Healthcare System, Florida, USA., Anasetti C; BMTCI H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA., Pidala J; BMTCI H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA.

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2019 Jan; Vol. 54 (1), pp. 85-89. Date of Electronic Publication: 2018 Jun 12.

A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.

Autor: Arai S; Department of Medicine/Division of Blood and Marrow Transplant, Stanford University School of Medicine, Stanford, California., Pidala J; Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Pusic I; Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine, St. Louis, Missouri., Chai X; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Jaglowski S; Division of Hematology, Internal Medicine, Ohio State University, Columbus, Ohio., Khera N; Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona., Palmer J; Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona., Chen GL; Department of Medicine/Division of Blood and Marrow Transplant, Stanford University School of Medicine, Stanford, California., Jagasia MH; Department of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee., Mayer SA; Mayer Weill Cornell Medical College, New York, New York., Wood WA; Department of Hematology/Oncology, University of North Carolina, Chapel Hill, North Carolina., Green M; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke Cancer Institute, Duke University, Durham, North Carolina., Hyun TS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Inamoto Y; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Storer BE; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Miklos DB; Department of Medicine/Division of Blood and Marrow Transplant, Stanford University School of Medicine, Stanford, California., Shulman HM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Martin PJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Sarantopoulos S; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke Cancer Institute, Duke University, Durham, North Carolina., Lee SJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Flowers ME; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. mflowers@fhcrc.org.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 Jan 15; Vol. 22 (2), pp. 319-27. Date of Electronic Publication: 2015 Sep 16.